metformin has been researched along with Neurodevelopmental Disorders in 3 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Neurodevelopmental Disorders: These are a group of conditions with onset in the developmental period. The disorders typically manifest early in development, often before the child enters grade school, and are characterized by developmental deficits that produce impairments of personal, social, academic, or occupational functioning. (From DSM-5).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin is a drug commonly used in individuals with type 2 diabetes, obesity, and impaired glucose tolerance." | 5.51 | Metformin treatment in young children with fragile X syndrome. ( Afzal, S; Biag, HMB; Hagerman, RJ; Manzano-Nunez, R; Potter, LA; Rajaratnam, A; Rivera, SM; Rosvall, A; Salcedo-Arellano, MJ; Schneider, A; Tassone, F; Wilkins, V, 2019) |
| "Metformin is a drug commonly used in individuals with type 2 diabetes, obesity, and impaired glucose tolerance." | 1.51 | Metformin treatment in young children with fragile X syndrome. ( Afzal, S; Biag, HMB; Hagerman, RJ; Manzano-Nunez, R; Potter, LA; Rajaratnam, A; Rivera, SM; Rosvall, A; Salcedo-Arellano, MJ; Schneider, A; Tassone, F; Wilkins, V, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biag, HMB | 1 |
| Potter, LA | 1 |
| Wilkins, V | 1 |
| Afzal, S | 1 |
| Rosvall, A | 1 |
| Salcedo-Arellano, MJ | 1 |
| Rajaratnam, A | 1 |
| Manzano-Nunez, R | 1 |
| Schneider, A | 1 |
| Tassone, F | 1 |
| Rivera, SM | 1 |
| Hagerman, RJ | 1 |
| Wood, H | 1 |
| Andrade, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for metformin and Neurodevelopmental Disorders
| Article | Year |
|---|---|
Major malformation risk, pregnancy outcomes, and neurodevelopmental outcomes associated with metformin use during pregnancy.
Topics: Abnormalities, Drug-Induced; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Infan | 2016 |
2 other studies available for metformin and Neurodevelopmental Disorders
| Article | Year |
|---|---|
Metformin treatment in young children with fragile X syndrome.
Topics: Child; Child, Preschool; Fragile X Syndrome; Humans; Hypoglycemic Agents; Male; Metformin; Neurodeve | 2019 |
Neurodevelopmental disorders: Metformin - a therapeutic option for fragile X syndrome?
Topics: Animals; Disease Models, Animal; Fragile X Syndrome; Metformin; Mice; Neurodevelopmental Disorders | 2017 |